The drugmaker posted a 57.5% YoY increase in net profit to ₹157 crore, compared with ₹100 crore a year earlier. Revenue rose 13% YoY to ₹1,265.4 crore from ₹1,119.7 crore, supported by robust growth in its Ex-US markets.
Revenue from Ex-US markets climbed 17% YoY to ₹587.5 crore ($63 million), while the US business grew 4% YoY to ₹628.2 crore ($68 million).
EBITDA increased 5.4% YoY to ₹230 crore, although the company said profitability was impacted by around ₹13.1 crore in higher operating and freight costs due to the ongoing geopolitical situation. As a result, the EBITDA margin narrowed to 18% from 19.5% a year ago.
During the quarter, Strides unlocked ₹100 crore through the sale of its majority stake in Pivot Path, its captive global capability centre (GCC), while retaining a meaningful interest in the business.
Managing Director and Group CEO Badree Komandur said investments in Ex-US markets are beginning to deliver results, supporting the company’s diversified growth strategy. He added that the company remains focused on cost optimisation to offset geopolitical cost pressures while pursuing sustainable and profitable growth.
